BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
RYTM upcoming catalysts
Rhythm Pharmaceuticals, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 4 readout(s) and 1 FDA event(s). Subscribe to RYTM (.ics).
Drugs: Setmelanotide
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No trials in this window. | ||||||
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-03-19 | FDA approval | approved | RHYTHM RYTM | IMCIVREE | Approved 2026-03-19: IMCIVREE (NDA213793 SUPPL9) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-03 | P2 | Rhythm Pharmaceuticals, Inc. RYTM | NCT06772597 A Study of Setmelanotide in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome; Obesity; Hyperphagia | active not recruiting | 18 |
| 2026-06-24 | P3 | Rhythm Pharmaceuticals, Inc. RYTM | NCT06596135 Open-Label Extension Study of Setmelanotide | Obesity Associated With Defects in Leptin-melanocortin Pathway | completed | 28 |
| 2026-02-09 | P2 | Rhythm Pharmaceuticals, Inc. RYTM | NCT06046443 A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | Hypothalamic Obesity | completed | 28 |
| 2025-12-19 | P3 | Rhythm Pharmaceuticals, Inc. RYTM | NCT05093634 EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | Obesity; Genetic Obesity | completed | 296 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.